Table 2 Multivariate analysis of PCDH17 expression for overall survival and disease-free survival in the TCGA cohort

PCDH17 ^a

2.04 (1.37–3.04)

< 0.001

1.89 (1.19–2.98)

0.007

Age^b

2.90 (1.94–4.34)

< 0.0001

1.52 (0.96–2.43)

0.08

WBC count^c

–

–

2.14 (1.36–3.39)

0.001

Cytogenetic risk^d

1.84 (1.28–2.65)

0.001

1.39 (0.95–2.04)

0.09

TP53 ^e

2.76 (1.37–5.55)

0.004

2.64 (0.93–7.47)

0.07

DNMT3A ^e

1.61 (1.05–2.48)

0.03

1.41 (0.85–2.33)

0.18

RUNX1 ^e

1.75 (0.94–3.26)

0.08

–

–

PCDH17 ^a

2.02 (1.13–3.62)

0.02

Age^b

2.38 (1.35–4.19)

0.003

WBC count^c

1.42 (0.81–2.48)

0.22

FLT3-ITD^f

–

–

TP53 ^e

–

–

DNMT3A ^e

1.99 (1.13–3.52)

0.02

IDH1 ^e

0.61 (0.21–1.78)

0.36